Information Provided By:
Fly News Breaks for May 26, 2016
GWPH
May 26, 2016 | 09:55 EDT
BofA/Merrill analyst Tazeen Ahmad met with GW Pharmaceuticals' CEO Justin Gover and investors on Tuesday and discussed the phase 3 trial of Epidiolex for Lennox-Gastaut syndrome. Ahmad continues to expect the trial to show statistical significance and said the NDA submission to the FDA is on track for 1H 2017. The analyst rates GW Pharmaceuticals a Buy with a $165 price target, mainly driven by his outlook for Epiodiolex and the potential for a scientifically validated cannabinoid therapy having a wide use in both orphan and non-orphan indications.
News For GWPH From the Last 2 Days
There are no results for your query GWPH